MagGenome

Kochi, India Founded: 2014 • Age: 12 yrs Minicorn
Nucleic acid extraction kits are developed using nanoparticle technology.

About MagGenome

MagGenome is a Healthcare company based in Kochi (India) founded in 2014 by Sam Santhosh and Sreedhar Santhosh. Nucleic acid extraction kits are developed using nanoparticle technology. MagGenome has raised $1.11 million across 4 funding rounds from investors including S Arumugam, Emerge Ventures and SCI Ventures. The company has 30 employees. MagGenome was last valued at $3.13 million in March 2020. Its Indian entity Maggenome Technologies Private Limited reported revenue of β‚Ή86.2 Lakh. MagGenome offers products and services including XpressDNA Blood Kit, XpressDNA Saliva Kit, XpressDNA Tissue Kit, XpressPure Beads, and MagStable DNA Saliva Collection Kit. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents.

Company details

MagGenome was founded in 2014 in Kochi, India, within the biotechnology sector. Genomic DNA extraction kits are provided through nanoparticle synthesis technology. Operations include the production of kits such as XpressDNA Blood mini kit and XpressDNA TissueCell line mini kit, along with the affinity resin-based XpressAffinity kit. Emphasis is placed on future diagnostics and therapeutic applications involving nanoparticle technology.

  • Headquarters Kochi, India
  • Employees 30
  • Founders Sam Santhosh, Sreedhar Santhosh
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website maggenome.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Maggenome Technologies Private Limited
  • Date of Incorporation 25 May, 2015
  • Jurisdiction Ernakulam, Kerala, India
Key Metrics
  • Annual Revenue
    ₹86.2 Lakh

    FY 2025 · -6% YoY

  • Net Loss
    -₹2.64 Cr

    FY 2025 · -307% margin

  • EBITDA
    -₹2.38 Cr

    FY 2025 · -277% margin

  • Total Equity Funding
    $1.11M (USD)

    in 4 rounds

  • Latest Funding Round
    $175.58K (USD), Angel Round

    Mar 2020

  • Investors
  • Employee Count
    30

Products & Services of MagGenome

MagGenome offers a comprehensive portfolio of products and services, including XpressDNA Blood Kit, XpressDNA Saliva Kit, XpressDNA Tissue Kit, XpressPure Beads, and MagStable DNA Saliva Collection Kit.

XpressDNA Blood Kit
DNA Extraction

Kit for high-yield DNA extraction from blood samples.

XpressDNA Saliva Kit
DNA Extraction

Kit for DNA extraction from saliva for testing.

XpressDNA Tissue Kit
DNA Extraction

Kit for DNA extraction from tissue samples.

XpressPure Beads
PCR Cleanup

Beads for removing impurities from PCR reactions.

MagStable DNA Saliva Collection Kit
Sample Collection

Kit for collecting and transporting saliva DNA.

Apps and channels of MagGenome

its YouTube channel MagGenome has 69 subscribers and 22 videos.

MagGenome
YouTube 69 subscribers 22 videos Music
Open channel

Videos from MagGenome

The most watched videos on MagGenome's YouTube channel, MagGenome (69 subscribers). Click a video to play it here.

Dr C N Ramchand's interview by The Economic Times, Health World.
520 views
XpressDNA Stool Kit | Stool DNA Extraction Protocol
418 views
AMDP 2022 Conference Highlights
376 views
XpressDNA Bacteria Kit | Bacterial DNA Extraction Protocol
376 views

More on MagGenome.

Funding Insights of MagGenome

MagGenome has successfully raised a total of $1.11M across 4 strategic funding rounds. The most recent funding activity was a Angel Round of $175.58 thousand completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.11M
  • Total Rounds 4
  • Last Round Angel Round β€” $175,575
  • First Round $189,772

    (Jan 2016)

  • Investors Count 3

All 4 funding rounds of MagGenome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2020$175,575Angel Round$3.13MS Arumugam
–
Feb 2019$176,836Angel Round–S Arumugam
–
Feb 2018$570,250Angel Round$2.54MS Arumugam
–
Jan 2016$189,772Seed$β€’β€’β€’β€’β€’Emerge Ventures
Valuation history
DateValuationStage
Mar 2020$3.13Mβ€’β€’β€’β€’β€’β€’β€’β€’
Feb 2018$2.54Mβ€’β€’β€’β€’β€’β€’β€’β€’

Last known valuation $3.13M (Mar 2020). 3 investors in total: 2 institutional and 1 angel.

Investors in MagGenome

MagGenome has secured backing from 3 investors, including angel and venture fund investors. Prominent investors backing the company include S Arumugam, Emerge Ventures and SCI Ventures.

All
Venture Fund
Angel
InvestorDescriptionFounded YearDomainLocation
Growth stage tech and life sciences focused VC firm investing primarily in India and the US
emergeout.comSingapore, Singapore
Investments in women-led US companies are made by SCI Ventures.
sci-ventures.comBaltimore, United States

S Arumugam

unknown_2cc470cd4b694d26b
Premium access

Investor details for MagGenome

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Maggenome Technologies Private Limited (MagGenome)

Maggenome Technologies Private Limited is the primary company behind MagGenome. The board of Maggenome Technologies Private Limited currently have 3 directors; the longest-serving is Balamaniamma Madathinkal Raghavan Nair, appointed in 2015. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Balamaniamma Madathinkal Raghavan Nair
DIN 02231058
Director25 May 201511 yrs 5 moMaggenome Technologies Private Limited
Chaniyilparampu Nanappan Ramchand
DIN 05166709
Director15 Jun 20233 yrs 4 moMaggenome Technologies Private Limited
Jegatheesan Mohan
DIN 10609208
Director20 Aug 20251 yr 2 moMaggenome Technologies Private Limited

People of MagGenome

4 people are tracked at MagGenome (3 in leadership, 1 in team); the tracked headcount is 30.

NameRoleGroup
Sam Santhosh
Co-Founder & ChairmanLeadership
Co-FounderLeadership
Ramchand CN
CEOLeadership
Nirali Kargathara
Techno Commercial ExecutiveTeam
Premium access

Complete people profiles for MagGenome

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of MagGenome

Figures of Maggenome Technologies Private Limited, the primary company behind MagGenome, for FY 2025. Revenue was ₹86.2 Lakh (-6% year on year). Net loss was -₹2.64 Cr (-307% margin). EBITDA was -₹2.38 Cr (-277% margin). Revenue has grown at a compounded annual rate of -65% over three years and +6% over five years.

  • ₹86.2 LakhRevenue · FY 2025 · -6% YoY
  • -₹2.64 CrNet loss · -307% margin
  • -₹2.38 CrEBITDA · -277% margin
  • ₹4.4 LakhPaid-up capital
  • 30Employees (provident fund records)
  • -65%Revenue CAGR, 3 years
  • +6%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Maggenome Technologies Private Limited are on its company page.

Premium access

Detailed financial statements for MagGenome

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of MagGenome

4 dated milestones of MagGenome across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded MagGenome is founded.
  2. Funding First funding round of $190K.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Angel Round, of $176K.

Web traffic of MagGenome

The website of MagGenome (maggenome.com) receives about 2.4K visits a month.

  • Monthly visits
    2.4K

    ▼ 70.2% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Maggenome

Premium access

Complete news archive for MagGenome

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about MagGenome

MagGenome was founded in 2014 and raised its 1st funding round 2 years after it was founded.

MagGenome is headquartered in Kochi, India. It is registered at Kochi, Kerala, India.

MagGenome is a funded company, having raised a total of $1.11M across 4 funding rounds to date. The company's 1st funding round was a Seed of $189.77K, raised on Jan 2016.

MagGenome has 30 employees.

The primary company behind MagGenome, Maggenome Technologies Private Limited, reported revenue of β‚Ή86.2 Lakh for FY 2025, down 6% year on year.

MagGenome was founded in 2014 in Kochi, India, within the biotechnology sector. Genomic DNA extraction kits are provided through nanoparticle synthesis technology. Operations include the production of kits such as XpressDNA Blood mini kit and XpressDNA TissueCell line mini kit, along with the affinity resin-based XpressAffinity kit. Emphasis is placed on future diagnostics and therapeutic applications involving nanoparticle technology.

MagGenome offers XpressDNA Blood Kit, XpressDNA Saliva Kit, XpressDNA Tissue Kit, XpressPure Beads, and MagStable DNA Saliva Collection Kit.

MagGenome has 3 investors. Key investors include S Arumugam, Emerge Ventures, and SCI Ventures.

The valuation of MagGenome is $3.13M as of Mar 2020.

MagGenome operates through Maggenome Technologies Private Limited.

The legal entities of MagGenome currently have 3 directors, including Balamaniamma Madathinkal Raghavan Nair, Chaniyilparampu Nanappan Ramchand, Jegatheesan Mohan.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available